Skip to main content
. 2020 Jan 3;99(1):e18462. doi: 10.1097/MD.0000000000018462

Figure 1.

Figure 1

The serum levels of interleukin 26 (IL-26) and hepatitis B virus (HBV) DNA in healthy controls and patients with chronic hepatitis B (CHB). The serum levels of HBV DNA (A) and IL-26 (B) in 28 healthy controls and 30 CHB patients were determined at weeks 0 (baseline), 12, 24, 36, and 52 after telbivudine (LdT) treatment. C. Hepatitis B e antigen (HBeAg)-negative patients (n = 10) were randomly selected at week 24 and 52 post LdT treatment, respectively. The serum IL-26 levels of HBeAg-positive patients at baseline (n = 30) and HBeAg-negative patients (n = 10) at week 24 or 52 were measured. Data are presented as mean ± standard deviation (SD). ∗P < .05, ∗∗P < .01 and ∗∗∗P < .001. HBV = hepatitis B virus, HC = healthy control, IL-26 = interleukin 26, w = week.